# Bankbiotech

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/bankbiotech

- Industry: Pharmaceuticals
- Headquarters: Wuhan, China
- Total disclosed funding: $1.5M
- Latest round: Angel (Aug 30, 2022)
- Investors on record: 2

## About

Established in 2011 and based in Wuhan, China, Bankbiotech has long been committed to the development of innovative antibody drugs and has built a comprehensive multi-dimensional antibody drug development platform. The company's founder, Rui Gong, has a PhD from Wuhan University, worked in antibody research at the National Institutes of Health, and is a researcher and doctoral supervisor at the Wuhan Institute of Virology, Chinese Academy of Sciences.

The company has built a novel nano-antibody technology platform to develop innovative antibody drugs. With the proprietary technology, the company has effectively enhanced the stability and anti-aggregation ability of nano-antibodies and extended the plasma half-life to improve the drug-forming properties of nano-antibody drugs. Currently, Bankbiotech has obtained several nanobody drug candidates against viral infectious diseases.

The company raised an angel funding in August 2022, this round of funding is mainly used for the development of innovative antiviral drugs based on the original novel nano-antibody technology. We expect to use 2-3 years to obtain clinical approvals for 2-3 innovative drugs.

## Funding rounds

- Angel, Aug 30, 2022, $1.5M — East Lake High Technology Equity Investment Management, Baiying Bio-industry Investment

## Investors

- East Lake High Technology Equity Investment Management (https://capitalatlas.ai/funds/east-lake-high-technology-equity-investment-management) — Angel
- Baiying Bio-industry Investment (https://capitalatlas.ai/funds/baiying-bio-industry-investment) — Angel